A detailed history of Royal Bank Of Canada transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,924 shares of ORIC stock, worth $58,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,924
Previous 6,291 10.06%
Holding current value
$58,854
Previous $44,000 59.09%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.52 - $11.9 $4,760 - $7,532
633 Added 10.06%
6,924 $70,000
Q2 2024

Aug 14, 2024

BUY
$6.63 - $12.93 $32,540 - $63,460
4,908 Added 354.88%
6,291 $44,000
Q1 2024

Nov 05, 2024

SELL
$8.04 - $16.03 $39,460 - $78,675
-4,908 Reduced 78.02%
1,383 $19,000
Q1 2024

May 15, 2024

SELL
$8.04 - $16.03 $81,549 - $162,592
-10,143 Reduced 88.0%
1,383 $19,000
Q4 2023

Feb 14, 2024

BUY
$5.41 - $9.43 $26,898 - $46,885
4,972 Added 75.86%
11,526 $106,000
Q3 2023

Nov 14, 2023

BUY
$6.05 - $9.28 $15,022 - $23,042
2,483 Added 60.99%
6,554 $39,000
Q2 2023

Aug 14, 2023

BUY
$4.95 - $8.4 $20,121 - $34,146
4,065 Added 67750.0%
4,071 $31,000
Q1 2023

May 15, 2023

SELL
$4.26 - $6.75 $788 - $1,248
-185 Reduced 96.86%
6 $0
Q4 2022

Feb 14, 2023

SELL
$2.41 - $5.89 $2,159 - $5,277
-896 Reduced 82.43%
191 $1,000
Q3 2022

Nov 14, 2022

BUY
$3.15 - $5.24 $1,795 - $2,986
570 Added 110.25%
1,087 $3,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.07 $9,247 - $24,214
-3,425 Reduced 86.88%
517 $2,000
Q1 2022

May 16, 2022

SELL
$4.54 - $16.1 $9,792 - $34,727
-2,157 Reduced 35.37%
3,942 $21,000
Q4 2021

Feb 14, 2022

BUY
$12.01 - $20.3 $32,775 - $55,398
2,729 Added 80.98%
6,099 $90,000
Q3 2021

Nov 15, 2021

BUY
$15.9 - $25.22 $21,465 - $34,047
1,350 Added 66.83%
3,370 $70,000
Q2 2021

Aug 16, 2021

BUY
$17.37 - $25.34 $35,087 - $51,186
2,020 New
2,020 $36,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $336M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.